Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to -$4.4 million.

  • CytomX Therapeutics' Other Working Capital Changes rose 8582.17% to -$4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.7 million, marking a year-over-year increase of 498.42%. This contributed to the annual value of -$118.3 million for FY2024, which is 3285.1% down from last year.
  • Latest data reveals that CytomX Therapeutics reported Other Working Capital Changes of -$4.4 million as of Q3 2025, which was up 8582.17% from -$17.1 million recorded in Q2 2025.
  • In the past 5 years, CytomX Therapeutics' Other Working Capital Changes ranged from a high of $45.9 million in Q4 2022 and a low of -$44.6 million during Q1 2025
  • For the 5-year period, CytomX Therapeutics' Other Working Capital Changes averaged around -$15.3 million, with its median value being -$17.1 million (2025).
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first surged by 54347.32% in 2022, then plummeted by 15962.9% in 2023.
  • CytomX Therapeutics' Other Working Capital Changes (Quarter) stood at -$10.3 million in 2021, then skyrocketed by 543.47% to $45.9 million in 2022, then tumbled by 153.07% to -$24.3 million in 2023, then crashed by 46.07% to -$35.6 million in 2024, then soared by 87.7% to -$4.4 million in 2025.
  • Its last three reported values are -$4.4 million in Q3 2025, -$17.1 million for Q2 2025, and -$44.6 million during Q1 2025.